News & Events
This will take effect October 1, 2012
Overview and Clinical Utility:
Effective October 1, 2012, Syphilis treponemal antibody screening will be performed on the Diasorin Liaison XL using one-step chemiluminescence immunoassay. The presence of antibodies to Treponema pallidum specific antigen, in conjunction with non-treponemal laboratory tests and clinical findings, may aid in the diagnosis of syphilis infection.
Click Here to read more.
This will take effect October 1, 2012
Overview and Clinical Utility:
Effective October 1, 2012, Vitamin D 25 Hydroxy will be performed on the Diasorin Liaison XL using chemiluminescent immunoassay. Vitamin D testing is used in the assessment of vitamin D sufficiency. Assay results should be used in conjunction with other clinical or laboratory data to assist the clinician in making individual patient management decisions.
Click Here to read more.
This will take effect September 24, 2012
Overview and Clinical Utility:
The Kleihauer-Betke Fetal Stain has been discontinued and replaced with Fetal Cell Assay by Flow Cytometry as the routine method to assess fetal-maternal hemorrhage quantification and recommended RhIG dosage.
The traditional slide based Kleihauer-Betke test is a time consuming method with high rates of inter-observer result variation and suboptimal precision. A more accurate, improved methodology is achieved via the Fetal Cell Assay by Flow Cytometry.
Click Here to read more.
This will take effect September 24, 2012
Overview and Clinical Utility:
Effective Monday, September 24, 2012, PathGroup Labs will offer a nine (9) panel urine drug screen in which all positive results will automatically reflex for confirmation testing. The test code for this new drug screen is USDC. The UDSL drug screen will continue to be available and orderable.
Click Here to read more.
This will take effect July 16, 2012
Overview and Clinical Utility:
Effective July 16, 2012, Rubella IgM antibody testing will be performed in house on the Bioplex 2200 using a multiplex flow immunoassay methodology. Rubella IgM (German measles) is a viral infection with worldwide distribution. Testing immediately post-exposure is of no value without a later convalescent specimen. While the presence of IgM antibodies suggests current or recent infection, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection or immunization.
Click Here to read more.
This will take effect July 16, 2012
Overview and Clinical Utility:
Effective July 16, 2012, Cytomegalovirus (CMV) IgM antibody testing will be performed on the Bioplex 2200 using a multiplex flow immunoassay methodology. CMV IgM is for the detection of human IgM antibodies to cytomegalovirus virus in human serum, as an aid in the determination of current or recent CMV infection.
Click Here to read more.
This will take effect July 9, 2012
OVERVIEW AND CLINICAL UTILITY:
Effective July 9, 2012, PathGroup Labs will only offer the following glucose tests. Test codes are unchanged, but test names have been standardized. The test panels below and associated reference ranges are based on recommendations by ADA and ACOG. Other glucose testing panels which are not endorsed by ADA or ACOG will no longer be available. Random glucose reference ranges will also be updated.
Click Here to read more.
This will take effect May 14, 2012
OVERVIEW AND CLINICAL UTILITY:
Effective May 14, 2012, Free and Total Testosterone for females and children will be performed in house. The concentration of free testosterone is derived from a mathematical expression based on the measurement of testosterone by LC/MS and sex hormone binding globulin. This test is suggested for women and children due to the improved sensitivity of testosterone by LC/MS. Reference ranges for Total Testosterone and Free Testosterone will be updated based on our patient population. Testosterone, the major androgenic hormone in humans, is commonly measured to aid in the diagnosis of clinical conditions related to its excess or deficiency. In addition, testosterone measurements are used to monitor testosterone replacement or anti-androgen therapy.
Click Here to read more.
This will take effect April 17, 2012
Clinical Utility:
A positive bias has been observed for the current Thyroglobulin reagent. A nation-wide shortage has made it impossible to order replacements for our current reagents. Therefore, effective April 17, 2012 PathGroup will switch testing to an alternate platform which will result in a change to expected values and the Reference Range for Thyroglobulin Antibodies. Thyroglobulin autoantibodies (TgAb) are often present in patients with autoimmune thyroid disease. This assay is intended to be used as an aid in the diagnosis of Hashimoto’s and Graves’ diseases which are autoimmune diseases affecting the thyroid gland. This assay is also necessary to identify patients whose serum contains Thyroglobulin autoantibodies that may interfere with serum Thyroglobulin measurements.
Click Here to read more.
This change will take effect February 24, 2012
Overview and Clinical Utility:
Effective February 24, 2012 PathGroup will implement the Optimized Serum Thyroid Peroxidase Antibody Assay. This assay is intended to be used as an aid for in vitro diagnostic use in the quantitative determination of autoantibodies against thyroid peroxidase in serum using the ADVIA Centaur XP systems.
Click Here to read more.
